3 February 2017 - Following the news that a new breast cancer medicine - palbociclib - from Pfizer has been ruled too expensive to justify its use on the NHS by NICE, ABPI's Commercial Director, Dr Richard Torbett said it was time to review the way in which modern cancer medicines are appraised as cost-effective.

​​"Today's ruling is another is blow for breast cancer patients and further reiterates why we need to change the way in which modern cancer medicines are evaluated. Scientific breakthroughs mean that more and more new cancer medicines are given in combination with existing treatments resulting in more patients living longer and living healthier.

Read ABPI Statement